Treatment of frontal fibrosing alopecia with microneedling and photodynamic therapy using 5-aminolevulinic acid in male and female adult participants – an open single group phase 2 study
This research study is investigating a new treatment for Frontal Fibrosing Alopecia (FFA), a type of hair loss that affects the front of the scalp. The treatment involves a technique called microneedling, where tiny needles gently prick the skin, combined with a special cream called Metvix and light therapy. The main goal is to see if this combination can reduce redness and thickening of the skin on the scalp over 32 weeks, compared to how it looked at the start. Researchers will also be checking for changes in hair density and how participants feel about their condition. Both men and women aged 18 and over can take part in this study.
At a glance
What is this study about?
This study is an investigation into Frontal Fibrosing Alopecia (FFA), a condition that causes hair loss, typically at the front of the scalp and sometimes affecting the eyebrows. It's an important area of research because finding effective treatments can significantly improve how people feel about their appearance and their quality of life. The study wants to find out if a particular combination treatment works well to help manage the symptoms of FFA.
The treatment being tested involves two main parts: microneedling and photodynamic therapy (PDT) using a cream called Metvix. Microneedling is a procedure where small, sterile needles are used to create tiny punctures in the skin. This is believed to help the skin absorb the special cream better and may also stimulate healing. Photodynamic therapy involves applying the Metvix cream to the affected area, which makes the skin more sensitive to light. Then, a special light is used to activate the cream, which is thought to reduce inflammation and improve skin health.
The main thing the researchers are looking for is whether this treatment can reduce problems like redness and thickened skin on the scalp after 32 weeks. They will compare these features to how they looked before the treatment started. They will also be checking other aspects, such as changes in how much hair is present and how participants themselves feel about their condition, to get a full picture of the treatment's effects.
Key takeaways
- This study explores a new treatment for Frontal Fibrosing Alopecia (FFA).
- The treatment involves microneedling with a special cream and light therapy.
- Researchers will check for reduced redness and skin thickening over 32 weeks.
- Both men and women aged 18 and above can participate.
- The study also looks at changes in hair density and how patients feel.
Who may be eligible?
This study is looking for adult volunteers of any gender who have been diagnosed with Frontal Fibrosing Alopecia (FFA). To join, you need to be at least 18 years old.
There isn't an upper age limit mentioned, so older adults are also welcome to consider taking part. The study is open to both men and women.
Always remember that your healthcare team will need to check if this study is suitable for you based on all your health information.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Frontal Fibrosing Alopecia (FFA)?
- Are you able to attend clinic visits for 32 weeks?
- Are you open to trying a treatment that involves microneedling and light therapy?
What does participation involve?
If you decide to take part in this study, the total duration will be 32 weeks. During this time, you will have several visits to the clinic. At these visits, the research team will assess your scalp, checking for things like redness and skin thickening. They will also measure how much hair you have. You'll also be asked to share how you feel about your condition by completing questionnaires.
The active treatment involves a combination of microneedling and the application of a special cream (Metvix), followed by light therapy. The full schedule of these treatments and assessments will be explained to you by the study team. Throughout the study, the research team will keep a close eye on your progress and any changes you experience.
Potential risks and benefits
Locations (1)
- —UnverifiedNorway
Common questions
What is Frontal Fibrosing Alopecia (FFA)?
FFA is a type of hair loss that usually affects the front of your scalp and can sometimes involve your eyebrows.
What is microneedling?
Microneedling is a procedure where tiny needles are used to make small punctures in the skin, which can help treatments work better.
What is Metvix cream?
Metvix is a special cream used in this study that makes the skin sensitive to light as part of a treatment called photodynamic therapy.
How long will the study last if I join?
The study will last for 32 weeks, which is about 8 months.
Can men and women join this study?
Yes, both adult men and women are welcome to take part in this study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.